Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting
- PMID: 18457467
- DOI: 10.2165/00126839-200809030-00002
Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting
Abstract
Background and objectives: Some evidence for the efficacy of botulinum toxin A as a preventive treatment for chronic primary headaches has been reported in randomized, controlled clinical studies. This study investigated the clinical profile of botulinum toxin A in a naturalistic clinical practice setting in a population of patients with cervical dystonia associated with chronic headache and a history of migraine.
Methods: This was a prospective, open-label, longitudinal study. Following a prospective run-in period, eligible patients were given three sets of botulinum toxin A injections at 8- to 12-week intervals over a 16- to 24-week period and were monitored for 3 months after the final injections. Efficacy was assessed in terms of headache-related disability (using the Migraine Disability Assessment [MIDAS] questionnaire), pain and emotional function (using the Short Pain Inventory [SPI]), quality of life (QOL, using the Short-Form-36 [SF-36] questionnaire) and patient-assessed headache frequency and severity, and medication use and its effectiveness. Safety was assessed as adverse events. The primary endpoint was the change in MIDAS score from baseline following treatment with botulinum toxin A.
Results: Twenty-four patients took part in the study and 17 (71%) completed the study. There were significant improvements in headache-related disability (MIDAS score), pain and emotional function (SPI), QOL (SF-36), headache frequency and medication use following treatment with botulinum toxin A (p < 0.05 for all endpoints). An efficacy response occurred within 8 weeks of treatment initiation and was maintained throughout the study duration. Botulinum toxin A was generally well tolerated.
Conclusions: This study demonstrated that botulinum toxin A is an effective and well tolerated preventive treatment for chronic headache in patients with cervical dystonia and a history of migraine. These results warrant further investigation in a large, randomized, controlled study.
Similar articles
-
Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.Headache. 2008 Jun;48(6):900-13. doi: 10.1111/j.1526-4610.2007.00953.x. Epub 2007 Nov 28. Headache. 2008. PMID: 18047501 Clinical Trial.
-
Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.Headache. 2012 Sep;52(8):1219-25. doi: 10.1111/j.1526-4610.2012.02164.x. Epub 2012 May 18. Headache. 2012. PMID: 22607530 Clinical Trial.
-
A pilot study of botulinum toxin A for headache in cervical dystonia.Headache. 2005 Sep;45(8):1073-7. doi: 10.1111/j.1526-4610.2005.05190.x. Headache. 2005. PMID: 16109123 Clinical Trial.
-
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside.Headache. 2003 Jul-Aug;43 Suppl 1:S25-33. doi: 10.1046/j.1526-4610.43.7s.5.x. Headache. 2003. PMID: 12887391 Review.
-
Botulinum toxin in migraine prophylaxis.J Neurol. 2004 Feb;251 Suppl 1:I8-11. doi: 10.1007/s00415-004-1103-y. J Neurol. 2004. PMID: 14991336 Review.
Cited by
-
Quality of life in idiopathic dystonia: a systematic review.J Neurol. 2019 Dec;266(12):2897-2906. doi: 10.1007/s00415-018-9119-x. Epub 2018 Nov 20. J Neurol. 2019. PMID: 30460447 Free PMC article.
-
Uses of Botulinum Toxin in Headache and Facial Pain Disorders: An Update.Toxins (Basel). 2025 Jun 21;17(7):314. doi: 10.3390/toxins17070314. Toxins (Basel). 2025. PMID: 40711126 Free PMC article. Review.
-
Will (or can) people pay for headache care in a poor country?J Headache Pain. 2012 Jan;13(1):67-74. doi: 10.1007/s10194-011-0398-1. Epub 2011 Nov 2. J Headache Pain. 2012. PMID: 22045235 Free PMC article.
-
Botulinum Toxin Therapy: A Comprehensive Review on Clinical and Pharmacological Insights.J Clin Med. 2025 Mar 16;14(6):2021. doi: 10.3390/jcm14062021. J Clin Med. 2025. PMID: 40142828 Free PMC article. Review.
-
SYNCHRONIZE: Real-World Retrospective Safety Analysis of Patients Treated with OnabotulinumtoxinA for More than One Therapeutic Indication.Toxins (Basel). 2024 Sep 29;16(10):420. doi: 10.3390/toxins16100420. Toxins (Basel). 2024. PMID: 39453196 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical